Summary:
To demonstrate the efficacy of PEMF treatment compared to sham treatment in patients with painful diabetic distal symmetric peripheral neuropathy (DSPN) when treatment is administered 30 minutes twice daily through a 4 month period. A 2 month open-label active treatment extention period is included to collect longer-term data on pain, medication use, quality of life and safety.
Qualified Participants Must:
• Be a diagnosed Type 1 or Type 2 Diabetic
•
Have pain due to DPN for at least 6 months prior to screening
•
Be between 22-80 years of age
Qualified Participants May Receive:
- Study related treatment (Provant device or sham device)
- Compensation for time and travel expenses
- Lab work provided (blood work, EKG, etc.)
- Oversight by a board certifiied physician